Related Experiment Video
Updated: Aug 15, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Pegylated interferon alpha-2a-associated life-threatening Evans' syndrome in a patient with chronic hepatitis C
Olivier Lambotte1, Moana Gelu-Simeon, Gwenola Maigne
1Department of Internal Medicine, Kremlin Bicêtre Hospital, AP-HP, 78 rue du Général Leclerc, 94275 Le Kremlin Bicêtre, France. olivier.lambotte@bct.ap-hop-paris.fr
Abstract:
In this report, we describe an unusual and unreported complication with the new licensed form of pegylated interferon alpha2a (PEG-IFN-alpha2a). We report the first case of severe autoimmune cytopenias, an Evans' syndrome, in a patient with chronic hepatitis C, 2 months after PEG-IFN-alpha2a initiation. Haemolytic anaemia and thrombocytopenia developed, complicated by gastric bleeding and brain haemorrhage. Outcome was favourable under immunosuppressive treatment. Treatment with PEG-IFN-alpha2a requires careful follow-up, as IFNalpha can induce or exacerbate autoimmune diseases.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Antiviral Nucleoside Inhibitors
Hepatic Encephalopathy
